Effective anti-tumor activity requires a systemic, rather than only a local, immune response at the tumor site. The findings from a new study may help clinicians pinpoint why only some cancer patients respond to immunotherapies.
Effective anti-tumor activity requires a systemic, rather than only a local, immune response at the tumor site. The findings from a new study may help clinicians pinpoint why only some cancer patients respond to immunotherapies.